retatrutide dosing trials Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Retatrutide Dosing Guide: 2mg–12mg Protocol

With microdosing, the initial dose may be as low as 0.05 milligrams weekly, with a slower increase in the dose than usual. Full doses can range all the way up to 2.4 milligrams per week, depending on the brand and the specific needs of the person being prescribed the medication

Starting with a lower dose can help mitigate these symptoms

Compounded GLP-1 microdose medications are only indicated when a prescribing practitioner determines they offer a significant difference from the FDA-approved product, as compounded medications are not reviewed by the FDA for safety, efficacy, or quality

Retatrutide is an investigational triple agonist activating GLP-1, GIP, and glucagon receptors simultaneously, producing greater weight reduction than single or dual agonists

In studies, people taking higher doses of orforglipron lost about 11% of their body weight over 72 weeks